Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I George

Showing results (301-310 of 307) with videos related to

Pageof 31
Sort By:
You have reached the last page of results.This site can display upto 307 results.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
Blood Advances|January 28, 2026
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER studyJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
The Journal of Allergy and Clinical Immunology|October 19, 2015
Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical ImmunologyKarin Hartmann, Luis Escribano, Clive Grattan, et al.
Hemasphere|December 13, 2021
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus ProposalPeter Valent, Cem Akin, Karin Hartmann, et al.
Cancer Medicine|August 18, 2018
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)Celalettin Ustun, Elizabeth Morgan, Erica E M Moodie, et al.
Blood Advances|May 18, 2021
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)Se Young Han, Krzysztof Mrózek, Jenna Voutsinas, et al.
NEJM Evidence|February 6, 2024
Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Mariana Castells, Hanneke Oude Elberink, et al.
Pageof 31

Showing results (301-310 of 307) with videos related to

Sort By:
Pageof 31
You have reached the last page of results.This site can display upto 307 results.
The Journal of Allergy and Clinical Immunology|April 15, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 yearsCem Akin, Vito Sabato, Jason Gotlib, et al.
Blood Advances|January 28, 2026
Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER studyJason Gotlib, Andreas Reiter, Deepti H Radia, et al.
The Journal of Allergy and Clinical Immunology|October 19, 2015
Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical ImmunologyKarin Hartmann, Luis Escribano, Clive Grattan, et al.
Hemasphere|December 13, 2021
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus ProposalPeter Valent, Cem Akin, Karin Hartmann, et al.
Cancer Medicine|August 18, 2018
Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)Celalettin Ustun, Elizabeth Morgan, Erica E M Moodie, et al.
Blood Advances|May 18, 2021
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)Se Young Han, Krzysztof Mrózek, Jenna Voutsinas, et al.
NEJM Evidence|February 6, 2024
Avapritinib versus Placebo in Indolent Systemic MastocytosisJason Gotlib, Mariana Castells, Hanneke Oude Elberink, et al.
Pageof 31